EUCTR2010-024014-60-IT进行中（未招募）1 期
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed with or without Cixutumumab as First-Line Therapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Carcinoma - ND
Eli Lilly and Company Limited, Indianapolis0 个研究点目标入组 220 人开始时间: 2010年12月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] The patient has histologically or cytologically confirmed, nonsquamous (adenocarcinoma/large cell or other) NSCLC. [2] The patient has Stage IV disease (AJCC Staging Manual, Seventh Edition; Edge et al. 2010) at the time of study entry. [3] Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to randomization, or after surgical resection performed at least 28 days prior to randomization. The patient may have no evidence of Grade =1 central nervous system (CNS) hemorrhage based on pretreatment magnetic resonance imaging (MRI) or intravenous (IV) contrast computed tomography (CT) scan (performed within 21 days before randomization). [4] The patient has measurable or nonmeasurable disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v. 1.1) guidelines (Eisenhauer et al. 2009; Attachment 6). [5] The patient is =18 years old. [6] The patient has an ECOG performance status (PS) of 0 or 1 (Oken et al. 1982; Attachment 7). [7] If the patient received prior adjuvant chemotherapy, the last dose of adjuvant treatment was administered at least 6 months prior to randomization. [8] The patient has adequate organ function, as evidenced by the following: • Adequate bone marrow reserve: absolute neutrophils (segmented and bands) count (ANC) =1500 cells/µL, hemoglobin =9.5 g/dL, and platelets =100000 cells/µL. • Hepatic: bilirubin =1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3 times ULN (or =5 times the ULN in the presence of known liver metastases). • Renal: The patient has adequate renal function as defined by serum creatinine =1.2 times the institutional ULN. If serum creatinine is above 1.2 times the ULN, the patient’s creatinine clearance must be =45 mL/min. [9] The patient has fasting serum glucose =100 mg/dL, and hemoglobin A1C =6%. If baseline nonfasting glucose =100 mg/dL, fasting glucose measurement is not required. [10] Females with reproductive potential: Must have a negative serum or urine pregnancy test within 7 days prior to the first dose of any study drug. [11] Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for 6 months following the last dose of any study drug. [12] The patient has the ability to understand and the willingness to sign a written informed consent form (ICF). [13] Patients with prior radiation therapy may be eligible for this study if they meet the following guidelines: • Previous radiation therapy is allowed to <25% of the bone marrow (Cristy and Eckerman 1987), but should have been limited and must not have included whole pelvis radiation. • Patients must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). • Prior thoracic radiotherapy must be completed 30 days before study enrollment. • Lesions that have been radiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy. • Palliative extrathoracic radiotherapy to preexisting lesions may continue on study; however, these lesions may not be included as sites of measurable disease. [14] The pa
排除标准
- •Patients must not have an uncontrolled intercurrent illness, leptomeningeal disease, or active infection requiring parenteral therapy.
研究者
相似试验
招募中
1 期
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanomanresectable or Metastatic MelanomaMedDRA version: 20.0Level: LLTClassification code: 10027481Term: Metastatic melanoma Class: 10029104CTIS2023-505672-30-00F. Hoffmann-La Roche AG101
招募中
2 期
A Randomized Phase 2 Study of TRK-950 when Used in Combination withRamucirumab and Paclitaxel in Patients with Gastric CancerGastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaJPRN-jRCT2031230319Mori Yoshitaka146
进行中（未招募）
1 期
A Study in advanced squamous non small cell lung cancerStage IV Squamous Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 16.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003214-13-DEEli Lilly and Company189
进行中（未招募）
不适用
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung CancerDiseases of th respiratory systemKCT0001107Eli Lilly Korea15
进行中（未招募）
1 期
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell Lymphomaon-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaMedDRA version: 14.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012280-34-BEJanssen-Cilag International N.V.164